Viewing Study NCT02740569


Ignite Creation Date: 2025-12-24 @ 11:03 PM
Ignite Modification Date: 2026-02-25 @ 2:34 AM
Study NCT ID: NCT02740569
Status: COMPLETED
Last Update Posted: 2018-09-07
First Post: 2016-04-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement
Sponsor: Marmara University
Organization:

Study Overview

Official Title: Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement
Status: COMPLETED
Status Verified Date: 2018-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: OSASPI
Brief Summary: Scleroderma is an autoimmune disease with skin manifestations and may have pulmonary involvement. Obstructive sleep apnea (OSA) may also be seen in scleroderma. Less is known regarding the prevalence of OSA in scleroderma and its association with pulmonary involvement.
Detailed Description: Scleroderma is an autoimmune disease with skin manifestations and may have pulmonary involvement. OSA may also be seen in scleroderma. Less is known regarding the prevalence of obstructive sleep apnea in scleroderma and its association with pulmonary involvement.

The investigators would like to address the prevalence of OSA in patients with Scleroderma, using overnight cardiorespiratory polygraphy. Other comorbidities and pulmonary findings on computer tomography (CT) as well as lung function tests will be evaluated.

The investigators plan to include 60 patients.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: